Acumen Pharma announces new appointment

US clinical-stage drug developer Acumen Pharmaceuticals (Nasdaq: ABOS) has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen.

The company is developing ACU193, a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD).

“Dr Schacterle is a highly regarded leader who has successfully led global regulatory and quality activities across multiple neurologic and psychiatric therapeutic areas and all stages of development,” said Dan O’Connell, chief executive of Acumen. “She joins Acumen as we are making considerable clinical progress with our therapeutic candidate, sabirnetug, and continue to evolve our development strategy in advance of key clinical data. We are delighted to have someone with Amy’s deep expertise and experience in global regulatory and development strategy join our team in our quest to bring next-generation treatments to the Alzheimer’s patient community,” he noted.